10 Top Women in Biotech 2012

Life Sciences Tools & DiagnosticsMedical DevicesBiotechnology / Pharmaceuticals

Source: Fierce Biotech (11/8/12)

"Too few female professionals rise to senior executive roles in the biopharma industry, making the accomplishments of these women all the more exceptional."

Dr. Lynn Seely of Medivation ($MDVN) is spearheading the team that took Xtandi, a likely blockbuster for prostate cancer patients, all the way through the clinic to a first approval. At 23andMe, Anne Wojcicki aims to "connect" patients with genetic information that can help them take control of their own health. And Dr. Michelle Dipp of OvaScience wants to revolutionize the treatment of female infertility.

FierceBiotech's "10 Top Women in Biotech" honorees this year are top innovators in life sciences. Too few female professionals rise to senior executive roles in the biopharma industry, making the accomplishments of these women all the more exceptional. . .View Full Article

Healthcare Firm Uncovers AI Healthcare Growth Opportunity
Source: Streetwise Reports (06/06/2025)

Treatment.com AI Inc.'s (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) subsidiary Rocket Doctor was chosen by the Larta Institute to participate in its Bioscience and Healthcare Accelerator program. Read on to learn why one analyst says it is time to buy this company's stock.

Data Readout Positive from Trial of New Schizophrenia Drug
Source: Jason Kolbert (06/04/2025)

This new dopamine-serotonin system modulator showed sustained efficacy over 52 weeks and a favorable tolerability and safety profile, noted a D. Boral Capital report.

Biotech Firm Gains Exclusive Alzheimer's Rights in U.S. and Canada
Source: Streetwise Reports (05/30/2025)

Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) secures exclusive Alzheimer's clinic rights in Canada and key U.S. cities, positioning for a high-growth breakthrough. Learn how Algernon plans to launch cutting-edge clinics featuring PET scan technology and expand into a multibillion-dollar diagnostics market

A Health Sciences Stock Positioned To Break Out of a Giant Base Pattern
Source: Clive Maund (05/27/2025)

Technical Analyst Clive Maund explains why he thinks PreveCeutical Medical Inc. (PREV:CSE; PRVCF:OTCMKTS) is ready to break out and is rated a Strong Buy.